Patents by Inventor Clinton K. Matson

Clinton K. Matson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination MCL-1 inhibitors with anti-cancer agents
    Patent number: 11957693
    Abstract: The present disclosure generally relates to methods of treating cancer by administering an MCL-1 inhibitor and an anticancer agent.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: April 16, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Thomas F. Kenney, Clinton K. Matson, Chandrasekar Venkataramani
  • Combination MCL-1 inhibitors with anti-body drug conjugates
    Patent number: 11931424
    Abstract: The present disclosure generally relates to methods of treating or preventing cancer by administering an MCL-1 inhibitor and an antibody-drug conjugate, and optionally one or more additional anti-cancer agents. In particular, the MCL-1 inhibitor can be a compound of formula (I), (II) or (III), or compound A. The antibody-drug conjugate can comprises an anti-Trop-2 antibody and an anti-cancer agent (e.g., SN-38). The combination therapy for treating cancer can have synergistic effect.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: March 19, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Thomas F. Kenney, Clinton K. Matson, Chandrasekar Venkataramani
  • COMBINATION MCL-1 INHIBITORS WITH ANTI-CANCER AGENTS
    Publication number: 20230015985
    Abstract: The present disclosure generally relates to methods of treating cancer by administering an MCL-1 inhibitor and an anticancer agent.
    Type: Application
    Filed: June 9, 2022
    Publication date: January 19, 2023
    Inventors: Thomas F. Kenney, Clinton K. Matson, Chandrasekar Venkataramani
  • COMBINATION MCL-1 INHIBITORS WITH ANTI-BODY DRUG CONJUGATES
    Publication number: 20220409736
    Abstract: The present disclosure generally relates to methods of treating cancer by administering an MCL-1 inhibitor and an antibody-drug conjugate.
    Type: Application
    Filed: June 9, 2022
    Publication date: December 29, 2022
    Inventors: Thomas F. Kenney, Clinton K. Matson, Chandrasekar Venkataramani